These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 17265519

  • 21. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ.
    J Clin Oncol; 2005 Dec 01; 23(34):8671-8. PubMed ID: 16314627
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 01; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 23. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
    Cafiero F, Gipponi M, Lionetto R, P.A.R. Cooperative Study Group.
    J Surg Oncol; 2003 Jul 01; 83(3):140-6. PubMed ID: 12827681
    [Abstract] [Full Text] [Related]

  • 24. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD, Lee SI, Moon HY.
    Hepatogastroenterology; 2012 Jul 01; 59(113):104-7. PubMed ID: 22251527
    [Abstract] [Full Text] [Related]

  • 25. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
    Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Leichman CG, Macdonald JS.
    J Clin Oncol; 2006 Aug 01; 24(22):3542-7. PubMed ID: 16877719
    [Abstract] [Full Text] [Related]

  • 26. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
    Demir L, Somali I, Oktay Tarhan M, Erten C, Ellidokuz H, Can A, Dirican A, Vedat Bayoglu I.
    J BUON; 2011 Aug 01; 16(4):682-8. PubMed ID: 22331722
    [Abstract] [Full Text] [Related]

  • 27. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    Cancer Chemother Pharmacol; 2010 Sep 01; 66(4):659-67. PubMed ID: 20033812
    [Abstract] [Full Text] [Related]

  • 28. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A.
    J Clin Oncol; 2012 Sep 20; 30(27):3353-60. PubMed ID: 22915656
    [Abstract] [Full Text] [Related]

  • 29. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD, Colman LK, Lanier KS, Pajon ER, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N.
    J Clin Oncol; 2007 Jun 01; 25(16):2205-11. PubMed ID: 17470850
    [Abstract] [Full Text] [Related]

  • 30. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
    Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M, Bedenne L, Paillot B, Mini E, Sanches E, Welch J, Collette L, Praet M, Wils J.
    Eur J Cancer; 2008 Oct 01; 44(15):2204-11. PubMed ID: 18707870
    [Abstract] [Full Text] [Related]

  • 31. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
    Chau I, Norman AR, Cunningham D, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Tait D, Ross PJ, Shellito P, Oates JR.
    Eur J Cancer; 2005 Jul 01; 41(11):1551-9. PubMed ID: 16026692
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T, Fukuda T, Tsutani K.
    Clin Ther; 2007 Oct 01; 29(10):2256-67. PubMed ID: 18042483
    [Abstract] [Full Text] [Related]

  • 33. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
    André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A.
    J Clin Oncol; 2009 Jul 01; 27(19):3109-16. PubMed ID: 19451431
    [Abstract] [Full Text] [Related]

  • 34. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators.
    Lancet Oncol; 2014 Jul 01; 15(8):862-73. PubMed ID: 24928083
    [Abstract] [Full Text] [Related]

  • 35. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ.
    J Clin Oncol; 2008 May 10; 26(14):2336-41. PubMed ID: 18467725
    [Abstract] [Full Text] [Related]

  • 36. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
    Schippinger W, Jagoditsch M, Sorré C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    Br J Cancer; 2005 May 09; 92(9):1655-62. PubMed ID: 15856042
    [Abstract] [Full Text] [Related]

  • 37. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group.
    Acta Oncol; 2009 May 09; 48(3):368-76. PubMed ID: 19242829
    [Abstract] [Full Text] [Related]

  • 38. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, Chindavijak S, Khuhaprema T, Tantai N, Teerawattananon Y.
    Expert Rev Pharmacoecon Outcomes Res; 2015 May 09; 15(4):687-700. PubMed ID: 25327502
    [Abstract] [Full Text] [Related]

  • 39. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.
    Br J Cancer; 2006 Apr 24; 94(8):1122-9. PubMed ID: 16622438
    [Abstract] [Full Text] [Related]

  • 40. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.